New daily pill for breast cancer now available through early access program
NCT ID NCT07643831
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This expanded access program provides giredestrant, a daily oral drug, to people with ER-positive, HER2-negative breast cancer (early or advanced) who have limited treatment options. The goal is to offer early access before the drug is commercially available in the US. Participants take one 30 mg pill each day.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- giredestrant (a daily oral drug)
- What this could lead to
- If successful, this could offer a new treatment option for people with ER+/HER2- breast cancer who have limited alternatives.
- What could go wrong
- This is an expanded access program, not a formal trial, so data on effectiveness and safety are still being collected. It may not work for everyone and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ER+/HER2- EARLY OR LOCALLY ADVANCED/METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.